PubMed · 7908187
ISIS 5 possibilities.
Abstract
There are five major therapeutic groups for possible evaluation in the ISIS 5 trial. They include intravenous beta-blocking agents, glucose-insulin-potassium (GIK) therapy, newer anticoagulant and antithrombotic agents (hirudin and Hirulog), newer thrombolytic drugs such as recombinant plasminogen activator (r-PA) and surfactant and emulsifying agents such as Rheothrx. Many pilot studies are underway. Selection of agents will depend on the scientific interest of collaborating hospitals as well as the agent's safety and efficacy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
D Hunt. 1993. ISIS 5 possibilities.. https://doi.org/10.1111/j.1445-5994.1993.tb04762.x. https://searchpubmed.org/record/pubmed%3A7908187/isis-5-possibilities
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.